Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lundbeck reports second quarter financial results

Lundbeck reports second quarter financial results

13th August 2009

Lundbeck has posted its financial results for the second financial quarter of 2009, which show that the firm’s revenue for the period stands at 3,432 million Danish kroner (396.4 million pounds).

Of its total income, the European market constituted 1.7 million Danish kroner, while sales in the US raised 1.025 million Danish kroner.

The organisation also revealed that its key products – including Cipralex, Exiba and Azilect – all underwent double digit growth and continue to expand their market shares.

Additionally, sales of Xenazine are already contributing 81 million Danish Kroner to Lundbeck’s revenues.

President and chief executive of the company Ulf Wiinberg stated: “We are very pleased with the overall performance in the second quarter. Our businesses in Europe and international markets continue to show high growth.”

Earlier this month, Lundbeck and Solvay Pharmaceuticals announced the cessation of research and development activities into the Solvay’s bifeprunox therapy.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.